Side-by-side financials for AVTX and MRK. Every figure below comes from audited SEC filings and refreshed market data.
| Metric | AVTX | MRK |
|---|---|---|
| Market cap | - | $294.03 B |
| US-listed rank | - | #45 |
| Revenue (latest FY) | $59.00K | $65.01B |
| Net income (latest FY) | -$78.26M | $18.25B |
| Net margin | -132642.4% | 28.1% |
| P/E (trailing FY) | - | 16.1 |
| SEC filings | 997 | 996 |
In their latest fiscal years, Avalo Therapeutics, Inc. reported $59.00K in revenue while Merck & Co., Inc. reported $65.01B.
Full pages: Avalo Therapeutics, Inc. and Merck & Co., Inc., or browse the full rankings.